药品追溯码监管

Search documents
新华时评:严查!斩断回流药黑色链条
Xin Hua She· 2025-09-24 06:27
不过,高压态势下,仍有一些不法分子涉险牟利,让不合规药品流入百姓药盒。必须清醒认识到,彻底 斩断这一黑链条,绝非紧抓一个环节就能实现,需要各个环节拧紧"责任阀":药企、医疗机构、零售药 店应严格规范药品销售管理,杜绝药品流入非正规渠道;公众需提高风险意识,坚决不参与倒卖医保药 品。 新华社北京9月22日电 小小药片,连着每个人的生命安全,系着千家万户的健康福祉。近日,国家医保 局公布部分应用药品追溯码打击倒卖回流药骗取医保基金专项行动典型案例,展现了"码上监管"的新成 效,更透出彻底斩断黑色链条、从源头上治理回流药的决心。 药品安全无小事,民生底线不可破。唯有凝聚多方合力,织密监管的天罗地网,才能更好纠治回流药痼 疾,真正筑牢人民群众的用药安全屏障。(新华社记者彭韵佳 徐鹏航) 现实中,药贩子收售回流药的手段隐蔽且恶劣:有的以返利为诱饵,引诱参保人出售医保药品,进行非 法逐利;有的批量式"洗白",伪造票据为来路不明的药品"换个身份";有的在拆解重组回流药过程中, 无视药品存储避光、冷藏等要求,甚至肆意混淆剂量规格与药品种类。在"零本万利"的驱动下,回流药 成了药贩子牟取暴利的工具,严重侵蚀医保基金,也让百姓用 ...
严查!斩断回流药黑色链条
Xin Hua Wang· 2025-09-22 11:35
Core Viewpoint - The article emphasizes the importance of combating the illegal trade of "recycled drugs" to ensure public health and safety, highlighting the government's commitment to innovative regulatory measures to trace drug origins and prevent fraud [1][2]. Group 1: Regulatory Measures - The National Medical Insurance Administration has launched a special action to combat the illegal sale of recycled drugs, showcasing the effectiveness of "code-based supervision" [1]. - Starting from July 1, all medical insurance designated institutions are required to scan the unique "electronic ID" traceability code of each drug box, allowing for traceable drug origins and destinations [1]. Group 2: Risks of Recycled Drugs - Recycled drugs are often sourced through illegal channels, repackaged, or have their information altered, posing significant health risks to patients and disrupting market order [1]. - The methods used by drug traffickers include enticing insured individuals to sell insurance-covered drugs for profit, falsifying documents to disguise the origins of drugs, and neglecting proper storage conditions during the repackaging process [1]. Group 3: Collaborative Efforts - It is essential for pharmaceutical companies, medical institutions, and retail pharmacies to strictly manage drug sales and prevent drugs from entering informal channels [2]. - Public awareness and responsibility are crucial in preventing participation in the illegal trade of insurance-covered drugs, emphasizing that drug safety is a collective responsibility [2].
电商购药乱象丛生,真假药品混战,消费者该如何辨认正品?
Cai Fu Zai Xian· 2025-07-22 09:59
Core Viewpoint - The article highlights the rampant issues in online pharmaceutical sales, including counterfeit products, misleading labeling, and fraudulent reviews, which pose significant risks to consumers' safety and trust in e-commerce platforms [1][2][4]. Group 1: Counterfeit and Misleading Products - Numerous counterfeit products flood e-commerce platforms, often mimicking legitimate medications with similar packaging and names, leading to consumer confusion [1][2]. - Common tactics include "word games" where product names are altered to include terms like "repair" or "skin," and using similar color schemes to deceive consumers [2][4]. - Products labeled with "消字号" (disinfection) or "械字号" (medical device) are often misrepresented as effective medications, despite lacking rigorous clinical testing [4]. Group 2: Consumer Confusion and Regulatory Gaps - Consumers are often unfamiliar with the different product classifications, such as "国药准字" (national drug approval), which is the only legitimate identifier for approved medications [4]. - The approval process for non-drug products is less stringent, allowing potentially unsafe items to enter the market without adequate oversight [4]. Group 3: Fraudulent Practices on E-commerce Platforms - E-commerce sellers frequently engage in practices like fake reviews and inflated sales figures to mislead consumers into purchasing counterfeit products [6]. - The lack of a return policy for legitimate medications complicates consumer efforts to identify counterfeit products, as those that allow returns are likely not approved drugs [6]. Group 4: Regulatory Responses and Future Directions - The National Medical Insurance Administration is set to enhance drug traceability regulations starting January 1, 2025, aiming to create a comprehensive tracking system for pharmaceuticals [7]. - Experts emphasize the need for refined regulations to address the challenges posed by online drug sales, urging consumers to recognize legitimate products and utilize official tracking tools [8].
我国7月1日起全面实施医保药品扫码结算
Bei Jing Shang Bao· 2025-06-18 00:52
Group 1 - The National Healthcare Security Administration (NHSA) has made significant progress in addressing issues related to the management of medical insurance funds, particularly in combating illegal activities such as the resale of "returned drugs" [1] - "Returned drugs" refer to pharmaceuticals that have exited the legitimate distribution channels and re-entered the market, often through illegal means, posing risks to public health and safety [1] - The NHSA has launched a drug traceability information query function on its platform, allowing pharmacies to identify "returned drugs" through scanning, thereby ensuring the legality of drug sources [1][2] Group 2 - As of now, the NHSA has collected a total of 39.885 billion drug traceability codes to assist in combating the "returned drug" issue [2] - The NHSA plans to enhance the regulatory application of drug traceability codes, focusing on building a big data regulatory model to combat illegal drug trading and other violations [2] - The NHSA has initiated a special action to combat the production and sale of counterfeit and inferior drugs, with the first phase of verification tasks completed and several cases of "returned drugs" being addressed [2]